<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749251</url>
  </required_header>
  <id_info>
    <org_study_id>IDEAL BP Feasibility Study</org_study_id>
    <nct_id>NCT04749251</nct_id>
  </id_info>
  <brief_title>IDEAL Blood Pressure Management During Endovascular Therapy for Acute Ischemic Stroke</brief_title>
  <acronym>IDEAL</acronym>
  <official_title>IDEAL Blood Pressure Management During Endovascular Therapy for Acute Ischemic Stroke:A Feasibility Study of Randomisation to Individual vs. Fixed Blood Pressure Targets During Endovascular Therapy for Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Kassel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ideal blood pressure management strategy during endovascular therapy (EVT) for acute&#xD;
      ischemic stroke has not been defined. The aim of this pilot randomized clinical trial is to&#xD;
      determine whether randomization to a standard versus individual blood pressure management&#xD;
      strategy during the EVT procedure is feasible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute ischemic stroke (AIS) is a leading cause of death and long-term disability in the&#xD;
      Western world. Catheter-based removal of blood clots (endovascular therapy-EVT) is now the&#xD;
      standard of care for AIS caused by large vessel occlusions in the brain. The level of blood&#xD;
      pressure during the procedure appears to influence outcome. However, optimal blood pressure&#xD;
      management strategy has not been determined. Current blood pressure management strategy&#xD;
      during EVT typically aims to maintain blood pressure above or within predefined fixed targets&#xD;
      and is based on observational data and expert consensus rather than on high-quality&#xD;
      randomized evidence. Should blood pressure during removal of the occlusion be managed&#xD;
      according to the patient's individual blood pressure level or according to predefined fixed&#xD;
      blood pressure targets? The primary aim of this pilot trial is to determine whether&#xD;
      randomization to a procedure strategy targeting a predefined mean arterial blood pressure&#xD;
      (MABP) of 70-90 mmHg versus an individual strategy targeting Â± 10 % of a MABP reference value&#xD;
      is feasible. Secondary aims are to test recruitability and to detect challenges or obstacles&#xD;
      that would call for changes in the study design.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will be performed as a single center study, conducted at Aarhus University Hospital, Denmark. In the randomization process patients are stratified according to NIHSS (0-17 or &gt; 17) and age (18-65 or &gt; 66)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-month Modified Rankin Score (mRS). The mRS is a functional outcome score rankin from 0(best outcome) to 6 (death)</measure>
    <time_frame>Assessed up to 3 months after endovascular treatment</time_frame>
    <description>Functional outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recruitment rate (percentage)</measure>
    <time_frame>Assessed up 3 months after endovascular treatment</time_frame>
    <description>Percentage of admitted patients scheduled for EVT who is enrolled in the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to mean arterial blood pressure targets. Specifically, to determine the percentage of time outside the target treatment range</measure>
    <time_frame>Assessed 3 months after endovascular treatment</time_frame>
    <description>...Percentage of time outside the blood pressure targets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Data completeness (percentage)</measure>
    <time_frame>Assessed up to 3 months after endovascular treatment</time_frame>
    <description>Percentage of complete patient data study records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of reperfusion</measure>
    <time_frame>Assessed up to 3 months after endovascular treatment</time_frame>
    <description>Thrombolysis in Cerebral Infarction Score (TICI) score. The TICI score is a grading scale for angiographic outcomes rankin from 0 (no perfusion) to 3(complete perfusion)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Criteria for continuation to the definitive trial</measure>
    <time_frame>Assessed up to 3 months after endovascular treatment</time_frame>
    <description>The two arms are distinguishable on 3-month mRS with a trend statistical significant p-value below 0.1 or all of the following:&#xD;
Drop out rate is less than 10%&#xD;
Data completion is above 90%&#xD;
(A cumulated duration of 10 minutes outside the MABP targets is allowed) Additional cumulated time outside the respective MABP target range is on average less than 8% of the duration of the intervention</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Individual blood pressure management arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the EVT procedure(in general anesthesia), mean arterial blood pressure (MABP) during is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard blood pressure management arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the EVT procedure(in general anesthesia), mean arterial blood pressure (MABP) during is targeted to remain within a fixed range of 70-90 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Individualized blood pressure management</intervention_name>
    <description>During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within +/- 10 % of a reference value using vasoactive drugs and/or fluids</description>
    <arm_group_label>Individual blood pressure management arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard blood pressure management</intervention_name>
    <description>During the EVT procedure, mean arterial blood pressure (MABP) is targeted to remain within a fixed range of 70-90 mmHg</description>
    <arm_group_label>Standard blood pressure management arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Large vessel occlusion in anterior circulation in patients deemed treatable with EVT.&#xD;
&#xD;
          -  Living independently (mRS &lt; 2) before stroke.&#xD;
&#xD;
          -  EVT procedure feasible within 24 hours of symptom onset.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contra-indication/allergy to contrast agents, vasopressor agents or anaesthetics.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Medical condition where blood pressure targeting will be problematic (aorta&#xD;
             dissection, etc).&#xD;
&#xD;
          -  Participation in another trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mads Rasmussen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesia, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mads Rasmussen, MD, PhD</last_name>
    <phone>+4530566977</phone>
    <email>mads.rasmussen@vest.rm.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mads Rasmussen, MD, PhD</last_name>
      <phone>+4529265713</phone>
      <email>mads.rasmussen@vest.rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endovascular therapy</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This is a pilot study and the data may be made available to other researchers upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data may be shared after publication of main study results within a period of 5 years after publication</ipd_time_frame>
    <ipd_access_criteria>No criteria</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

